{"id":54036,"date":"2023-02-17T03:03:06","date_gmt":"2023-02-17T02:03:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/"},"modified":"2023-02-17T03:03:06","modified_gmt":"2023-02-17T02:03:06","slug":"u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","title":{"rendered":"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen"},"content":{"rendered":"
\n

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request to re-institute post-grant review (PGR) of the patentability of certain claims of Seagen\u2019s U.S. patent 10,808,039 (the \u2019039 patent).\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are very pleased that the PGR will be reinstituted given the PTO\u2019s determination that our petition presented compelling evidence of unpatentability of the \u2019039 patent,\u201d said Naoto Tsukaguchi, Corporate Officer and General Counsel, Daiichi Sankyo, Co., Ltd.\n<\/p>\n

\nOn December 23, 2020, Daiichi Sankyo filed a petition with the U.S. PTO for post-grant review contesting the patentability of certain claims of the \u2019039 patent. On April 7, 2022, the U.S. PTO initiated post-grant review of the \u2019039 patent to determine whether the claims of that patent should not have originally been granted. On July 15, 2022, the U.S. PTO granted Seagen\u2019s request for rehearing of the decision to institute post-grant review, deciding not to proceed with the PGR process. On February 7, 2023, a PTO Precedential Opinion Panel issued an order instructing the original PGR panel to decide whether the PGR should be reinstituted by applying the applicable standard of whether Daiichi Sankyo\u2019s petition presented compelling evidence of unpatentability.\n<\/p>\n

\nAbout Daiichi Sankyo<\/b>\n<\/p>\n

\nDaiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose \u201cto contribute to the enrichment of quality of life around the world.\u201d In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an \u201cInnovative Global Healthcare Company Contributing to the Sustainable Development of Society.\u201d For more information, please visit: www.daiichisankyo.com<\/a><\/i>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nGlobal\/Japan:<\/b>
Koji Ogiwara
\n
Daiichi Sankyo Co., Ltd.
\n
ogiwara.koji.ay@daiichisankyo.co.jp<\/a><\/i>
+81 3 6225 1126 (office)\n<\/p>\n

\nUS<\/b>
Kim Wix
\n
Daiichi Sankyo, Inc.
\n
kwix@dsi.com<\/a><\/i>
+1 908 992 6633\n<\/p>\n

\nInvestor Relations Contact:<\/b>
DaiichiSankyoIR@daiichisankyo.co.jp<\/a><\/i>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request to re-institute post-grant review (PGR) of the patentability of certain claims of Seagen\u2019s U.S. patent 10,808,039 (the \u2019039 patent). \u201cWe are very pleased that the PGR will be … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54036","6":"format-standard","7":"category-industry"},"yoast_head":"\nU.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request to re-institute post-grant review (PGR) of the patentability of certain claims of Seagen\u2019s U.S. patent 10,808,039 (the \u2019039 patent). \u201cWe are very pleased that the PGR will be ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-17T02:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230216005907\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen\",\"datePublished\":\"2023-02-17T02:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\"},\"wordCount\":381,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230216005907\\\/en\\\/808160\\\/21\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\",\"name\":\"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230216005907\\\/en\\\/808160\\\/21\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\",\"datePublished\":\"2023-02-17T02:03:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230216005907\\\/en\\\/808160\\\/21\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230216005907\\\/en\\\/808160\\\/21\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","og_locale":"en_US","og_type":"article","og_title":"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend","og_description":"TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request to re-institute post-grant review (PGR) of the patentability of certain claims of Seagen\u2019s U.S. patent 10,808,039 (the \u2019039 patent). \u201cWe are very pleased that the PGR will be ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-17T02:03:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230216005907\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen","datePublished":"2023-02-17T02:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/"},"wordCount":381,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230216005907\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","url":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","name":"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230216005907\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg","datePublished":"2023-02-17T02:03:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230216005907\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230216005907\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-re-institutes-post-grant-review-of-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54036"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54036\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}